Redmile Group increased its stake in Nurix Therapeutics by 4.4 million shares worth $63.43 million, bringing its total position to 11.31% of its assets. Despite the stock being down 6.5% over the past year, the fund's conviction in the biotech company reflects confidence in its lead BTK degrader program entering a registrational trial with strong Phase 1 data showing 83% objective response rate.

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

Nurix Therapeutics reported promising Phase 1 trial results for bexobrutideg, an investigational drug for relapsed or refractory chronic lymphocytic leukemia, showing an 83% objective response rate and a median progression-free survival of 22.1 months.

Nurix Therapeutics will host a webcast on December 8, 2025, to present new clinical data on bexobrutideg (NX-5948), an investigational BTK degrader for treating chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Nurix Therapeutics will present updated clinical data on bexobrutideg, a novel BTK degrader, at the ASH Annual Meeting, showcasing results in chronic lymphocytic leukemia and Waldenström macroglobulinemia treatments.

Nurix Therapeutics raised $250 million through a stock offering to fund clinical development of drug candidates targeting chronic lymphocytic leukemia and potential autoimmune indications.

Nurix Therapeutics launched a pivotal Phase 2 clinical trial (DAYBreak) for bexobrutideg, a potential BTK degrader treatment for relapsed or refractory chronic lymphocytic leukemia, with plans for a Phase 3 confirmatory study in 2026.

Nurix Therapeutics presented Phase 1a clinical data for NX-1607, a first-in-class oral CBL-B inhibitor, showing promising anti-tumor activity across multiple solid tumor types with evidence of immune activation and clinical benefits.

The non-Hodgkin's lymphoma market is expected to grow significantly between 2025-2034, driven by increasing incidence, advancements in targeted therapies, emerging treatments, and improved early detection efforts.

The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.

Nurix Therapeutics will host a webcast conference call to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress.

Sanofi agreed to acquire Blueprint Medicines for $9.5 billion, including the rare immunology disease medicine Ayvakit and a promising pipeline. The deal will expand Sanofi's rare and immunology portfolios.